Vimarsana
Biggest News Aggregation in the World

Page 12 - Published October News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Published October. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Published October Today - Breaking & Trending Today

FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis - Vimarsana News

FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.

Source: ajmc.com
ULM's annual Trunk or Treat set for Monday, Oct. 30 - Vimarsana News

ULM's annual Trunk or Treat set for Monday, Oct. 30

ULM’s annual Trunk or Treat event will take place on Monday, October 30, 2023, in the parking lot of Brown Stadium, at 340 Warhawk Way next to Malone Stadium, from 5:00-7:00 p.m.

Source: ulm.edu
Pussy Riot's Art and Activism will take centre Stage in Montreal - Vimarsana News

Pussy Riot's Art and Activism will take centre Stage in Montreal

Save the date: October 25th for the upcoming exhibition: Velvet Terrorism: Pussy Riot’s Russia.

ULM to host STEM Night for middle and high school students on Oct. 26 - Vimarsana News

ULM to host STEM Night for middle and high school students on Oct. 26

The ULM Science Fair Committee is hosting a STEM Night on October 26, 2023, in the ULM Museum of Natural History, located on the first floor of Hanna Hall at 708 University Ave., from 5:30 p.m. - 7:30 p.m. The event is free and open to the public. Local 6th-12th grade students with an interest in science and mathematics are encouraged to attend.

Source: ulm.edu
Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria - Vimarsana News

Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.